QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
NASDAQ:CALT

Calliditas Therapeutics AB (publ) (CALT) Competitors

$17.47
-0.05 (-0.29%)
(As of 06/5/2023 ET)
Compare
Today's Range
$16.85
$17.63
50-Day Range
$17.06
$25.61
52-Week Range
$10.82
$25.64
Volume
5,891 shs
Average Volume
11,168 shs
Market Capitalization
$520.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$79.00

CALT vs. BCYC, EOLS, PHAT, LQDA, ENTA, ZYME, ORGO, OCUL, ANAB, and IGMS

Should you be buying Calliditas Therapeutics AB (publ) stock or one of its competitors? The main competitors of Calliditas Therapeutics AB (publ) include Bicycle Therapeutics (BCYC), Evolus (EOLS), Phathom Pharmaceuticals (PHAT), Liquidia (LQDA), Enanta Pharmaceuticals (ENTA), Zymeworks (ZYME), Organogenesis (ORGO), Ocular Therapeutix (OCUL), AnaptysBio (ANAB), and IGM Biosciences (IGMS). These companies are all part of the "pharmaceutical preparations" industry.

Calliditas Therapeutics AB (publ) vs.

Bicycle Therapeutics (NASDAQ:BCYC) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, community ranking, earnings, risk, institutional ownership, profitability and dividends.

Bicycle Therapeutics presently has a consensus price target of $53.20, indicating a potential upside of 104.77%. Calliditas Therapeutics AB (publ) has a consensus price target of $79.00, indicating a potential upside of 352.20%. Given Calliditas Therapeutics AB (publ)'s higher probable upside, analysts plainly believe Calliditas Therapeutics AB (publ) is more favorable than Bicycle Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bicycle Therapeutics
0 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.91
Calliditas Therapeutics AB (publ)
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Bicycle Therapeutics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bicycle Therapeutics$14.46 million53.97-$112.72 million-$4.17-6.23
Calliditas Therapeutics AB (publ)$79.63 million6.54-$40.86 million-$1.45-12.05

In the previous week, Bicycle Therapeutics had 6 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 9 mentions for Bicycle Therapeutics and 3 mentions for Calliditas Therapeutics AB (publ). Bicycle Therapeutics' average media sentiment score of 0.33 beat Calliditas Therapeutics AB (publ)'s score of -0.36 indicating that Bicycle Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bicycle Therapeutics
0 Very Positive mention(s)
4 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Calliditas Therapeutics AB (publ)
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Bicycle Therapeutics has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500.

Bicycle Therapeutics received 84 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 67.09% of users gave Bicycle Therapeutics an outperform vote while only 59.46% of users gave Calliditas Therapeutics AB (publ) an outperform vote.

CompanyUnderperformOutperform
Bicycle TherapeuticsOutperform Votes
106
67.09%
Underperform Votes
52
32.91%
Calliditas Therapeutics AB (publ)Outperform Votes
22
59.46%
Underperform Votes
15
40.54%

Calliditas Therapeutics AB (publ) has a net margin of -43.26% compared to Bicycle Therapeutics' net margin of -801.45%. Bicycle Therapeutics' return on equity of -44.57% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company Net Margins Return on Equity Return on Assets
Bicycle Therapeutics -801.45% -44.57% -29.19%
Calliditas Therapeutics AB (publ) -43.26% -56.47% -23.60%

77.9% of Bicycle Therapeutics shares are owned by institutional investors. Comparatively, 3.1% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 10.2% of Bicycle Therapeutics shares are owned by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Bicycle Therapeutics beats Calliditas Therapeutics AB (publ) on 11 of the 18 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CALT vs. The Competition

MetricCalliditas Therapeutics AB (publ)Pharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$520.43M$5.48B$4.53B$6.26B
Dividend YieldN/A2.53%6.05%6.50%
P/E Ratio-12.057.51118.4113.78
Price / Sales6.54327.743,486.0388.34
Price / CashN/A20.5022.2723.57
Price / Book6.854.774.665.43
Net Income-$40.86M$145.25M$116.58M$192.41M
7 Day Performance-2.07%3.82%2.19%2.14%
1 Month Performance-31.79%2.02%1.52%3.55%
1 Year Performance-8.87%19.25%13.18%1.24%

Calliditas Therapeutics AB (publ) Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BCYC
Bicycle Therapeutics
1.7277 of 5 stars
$24.05
-0.7%
$53.20
+121.2%
+65.9%$512.39M$15.50M-5.77119
EOLS
Evolus
1.8434 of 5 stars
$9.00
+2.5%
$17.80
+97.8%
-31.8%$512.28M$148.62M-7.09167
PHAT
Phathom Pharmaceuticals
1.9365 of 5 stars
$11.40
-3.1%
$20.17
+76.9%
+62.8%$512.90MN/A-2.3477
LQDA
Liquidia
1.9503 of 5 stars
$7.94
-4.9%
$14.00
+76.3%
+105.8%$513.86M$16.94M-14.1852Positive News
ENTA
Enanta Pharmaceuticals
2.7257 of 5 stars
$23.80
-4.4%
$56.75
+138.4%
-40.1%$501.23M$86.16M-3.98155
ZYME
Zymeworks
2.4345 of 5 stars
$8.18
-0.8%
$12.44
+52.1%
+22.1%$524.92M$446.14M3.16455
ORGO
Organogenesis
2.4278 of 5 stars
$3.80
+0.8%
$10.00
+163.2%
-28.8%$498.79M$450.89M34.551,030
OCUL
Ocular Therapeutix
2.0852 of 5 stars
$6.39
+1.8%
$13.50
+111.3%
+120.4%$495.42M$51.49M-5.37228Positive News
ANAB
AnaptysBio
1.7813 of 5 stars
$18.55
-0.5%
$34.67
+86.9%
-10.7%$491.39M$10.29M-3.83102Positive News
IGMS
IGM Biosciences
2.562 of 5 stars
$11.58
+1.8%
$29.78
+157.1%
-17.6%$489.84M$1.59M-2.24192Positive News

Related Companies and Tools

This page (NASDAQ:CALT) was last updated on 6/5/2023 by MarketBeat.com Staff

My Account -